Ubs Asset Management Americas Inc Kala Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	BUY	$5.06 - $8.15 $124,951 - $201,256	24,694 Added 117.59%	45,694 $242,000
Q1 2021 May 14, 2021	SELL	$6.24 - $9.58 $176,592 - $271,114	-28,300 Reduced 57.4%	21,000 $141,000
Q4 2020 Mar 01, 2021	BUY	$6.28 - $8.79 $6,908 - $9,668	1,100 Added 2.28%	49,300 $334,000
Q3 2020 Nov 13, 2020	BUY	$7.5 - $11.11 $39,000 - $57,772	5,200 Added 12.09%	48,200 $361,000
Q2 2020 Aug 14, 2020	BUY	$8.33 - $13.79 $358,190 - $592,970	43,000 New	43,000 $451,000
Q1 2018 May 14, 2018	SELL	$12.26 - $18.98 $242,478 - $375,386	-19,778 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$13.68 - $23.17 $306,732 - $519,517	-22,422 Reduced 53.13%	19,778 $0
Q3 2017 Nov 13, 2017	BUY	$19.86 - $26.53 $838,092 - $1.12 Million	42,200	42,200 $0

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $8.67M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.